TECX - NASDAQ
Tectonic Therapeutic, Inc.
$29.13
+2.5%Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangiectasia; bi-functional GPCR modulator for indication of fibrosis; and GPCR modulators. Tectonic Therapeutic, Inc. is based in Watertown, Massachusetts.
At a Glance
Live Snapshottecx
Research Development Expenses
Last Annual Value
63.49M
3-Year CAGR
35%
5-Year CAGR
-6%
10-Year CAGR
37%
Tectonic Therapeutic, Inc. Competitors Analysis of research-development-expenses
| Company | research-development-expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
 Tectonic Therapeutic, Inc. NASDAQ:TECX | 63.49M | 19.8% | 42.1% | 37.3% | |
 Neumora Therapeutics, Inc. Common Stock NASDAQ:NMRA | 176.06M | 7.2% | -3.7% | N/A | |
 Alector, Inc. NASDAQ:ALEC | 123.06M | -13.8% | -8.3% | 24.6% | |
 Capricor Therapeutics, Inc. NASDAQ:CAPR | 84.45M | 32.3% | 44.1% | 18.1% | |
 Kyverna Therapeutics, Inc. NASDAQ:KYTX | 133.72M | 40.5% | 38.9% | N/A | |
 Tenaya Therapeutics, Inc. NASDAQ:TNYA | 68.61M | -11.2% | 4.8% | N/A | |
 Vanda Pharmaceuticals Inc. NASDAQ:VNDA | 109.27M | 12.5% | 7.7% | 14.1% | |
 Aldeyra Therapeutics, Inc. NASDAQ:ALDX | 25.66M | -4.5% | -10.6% | 6.9% | |
 Larimar Therapeutics, Inc. NASDAQ:LRMR | 154.22M | 77.3% | 32.1% | 14.5% | |
 Lyell Immunopharma, Inc. NASDAQ:LYEL | 158.68M | -4.6% | 2.7% | N/A | |
 Alto Neuroscience, Inc. NYSE:ANRO | 45.62M | 14.6% | 40.4% | N/A |
Tectonic Therapeutic, Inc. Fair Value Envelope
Related Guides
Continue your TECX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.